ethyl 6-(2-(1H-imidazol-1-yl)-1-{[(4-methoxyphenyl)methoxy]methyl}ethoxy)-2(E)-hexenoate | 109786-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 6-(2-(1H-imidazol-1-yl)-1-{[(4-methoxyphenyl)methoxy]methyl}ethoxy)-2(E)-hexenoate
• 英文别名: 6-[2-Imidazol-1-yl-1-(4-methoxy-benzyloxymethyl)-ethoxy]-hex-2-enoic acid ethyl ester；ethyl (E)-6-[1-imidazol-1-yl-3-[(4-methoxyphenyl)methoxy]propan-2-yl]oxyhex-2-enoate
• CAS: 109786-93-8
• 化学式: C₂₂H₃₀N₂O₅
• 分子量: 402.491
• InChiKey: MHCCMXKLWQCLPB-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  29
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  71.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 6-(2-(1H-imidazol-1-yl)-1-{[(4-methoxyphenyl)methoxy]methyl}ethoxy)-2(E)-hexenoate 在 氢氧化钾 作用下， 反应 1.0h， 以57%的产率得到6-(2-(1H-imidazol-1-yl)-1-{[(4-methoxyphenyl)methoxy]methyl}ethoxy)-2(E)-hexenoic acid
  参考文献：
  名称：

  Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (.+-.)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)methoxy]methyl]ethoxy]hexanoic acids

  摘要：

  A series of substituted omega-[2-(1H-imidazol-1-yl)ethoxy]alkanoic acid derivatives were synthesized and evaluated for their ability to inhibit thromboxane synthase both in vitro and in vivo. Compound 13 was identified as a potent and selective competitive inhibitor of human platelet thromboxane synthase having a Ki value of 9.6 X 10(-8) M. In collagen-treated human whole blood, 13 potentiated levels of 6-keto PGF1 alpha. Enantiospecific syntheses afforded the R and S enantiomers of 13, of which the S enantiomer 13b was the more potent. Compounds 13 and 13b were potent in vivo inhibitors of thromboxane synthase with good oral activity and duration of action.

  DOI：

  10.1021/jm00393a022
• 作为产物：
  描述：

  α-<<(4-methoxyphenyl)methoxy>methyl>-1-H-imidazole-1-ethanol 在 硫酸 、 sodium hydride 作用下， 以 苯 为溶剂， 反应 17.5h， 生成 ethyl 6-(2-(1H-imidazol-1-yl)-1-{[(4-methoxyphenyl)methoxy]methyl}ethoxy)-2(E)-hexenoate
  参考文献：
  名称：

  Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (.+-.)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)methoxy]methyl]ethoxy]hexanoic acids

  摘要：

  A series of substituted omega-[2-(1H-imidazol-1-yl)ethoxy]alkanoic acid derivatives were synthesized and evaluated for their ability to inhibit thromboxane synthase both in vitro and in vivo. Compound 13 was identified as a potent and selective competitive inhibitor of human platelet thromboxane synthase having a Ki value of 9.6 X 10(-8) M. In collagen-treated human whole blood, 13 potentiated levels of 6-keto PGF1 alpha. Enantiospecific syntheses afforded the R and S enantiomers of 13, of which the S enantiomer 13b was the more potent. Compounds 13 and 13b were potent in vivo inhibitors of thromboxane synthase with good oral activity and duration of action.

  DOI：

  10.1021/jm00393a022

文献信息

• MANLEY, PAUL W.;TUFFIN, DAVID P.;ALLANSON, NIGEL M.;BUCKLE, PHILIP E.;LAD+, J. MED. CHEM., 30,(1987) N 10, 1812-1818
  作者：MANLEY, PAUL W.、TUFFIN, DAVID P.、ALLANSON, NIGEL M.、BUCKLE, PHILIP E.、LAD+

  DOI：——

  日期：——
• Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (.+-.)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)methoxy]methyl]ethoxy]hexanoic acids
  作者：Paul W. Manley、David P. Tuffin、Nigel M. Allanson、Philip E. Buckle、Nagin Lad、Steve M. F. Lai、David O. Lunt、Roderick A. Porter、Patricia J. Wade

  DOI：10.1021/jm00393a022

  日期：1987.10

  A series of substituted omega-[2-(1H-imidazol-1-yl)ethoxy]alkanoic acid derivatives were synthesized and evaluated for their ability to inhibit thromboxane synthase both in vitro and in vivo. Compound 13 was identified as a potent and selective competitive inhibitor of human platelet thromboxane synthase having a Ki value of 9.6 X 10(-8) M. In collagen-treated human whole blood, 13 potentiated levels of 6-keto PGF1 alpha. Enantiospecific syntheses afforded the R and S enantiomers of 13, of which the S enantiomer 13b was the more potent. Compounds 13 and 13b were potent in vivo inhibitors of thromboxane synthase with good oral activity and duration of action.